Shares of Pieris Pharmaceuticals, Inc. (PIRS) Wednesday surged over 77% after the biopharmaceutical company announced a merger deal with Palvella Therapeutics, Inc.PIRS is currently trading at $14.10, up $6.16 or 77.52%, on the Nasdaq. The stock opened its trading at $13.12 after closing Tuesday at $7.94.

生物制药公司Pieris Pharmaceuticals，Inc.（PIRS）宣布与Palvella Therapeutics，Inc.达成合并协议后，该公司股价周三飙升逾77%。PIRS目前在纳斯达克的交易价格为14.10美元，上涨6.16美元，涨幅77.52%。该股周二收于7.94美元，开盘价为13.12美元。

The stock has traded between $6.20 and $41.76 in the past 52-week period.Under the terms of the merger agreement, Pieris will issue shares of Pieris common stock to pre-merger Palvella stockholders as merger consideration in exchange for the cancellation of shares of capital stock of Palvella, and Palvella will become a wholly-owned subsidiary of Pieris..

该股在过去52周的交易价格在6.20美元至41.76美元之间。根据合并协议的条款，Pieris将向合并前的Palvella股东发行Pieris普通股作为合并对价，以换取Palvella股本的取消，Palvella将成为Pieris的全资子公司。。

Pre-merger Pieris stockholders are expected to own approximately 18% of the combined company and pre-merger Palvella stockholders are expected to own approximately 82% of the combined company.The combined company is expected to have about $80.5 million of cash and cash equivalents at closing of the proposed merger and concurrent private financing, inclusive of the net proceeds expected to be received in the concurrent private financing and after deducting operating expenses incurred prior to closing and estimated transaction expenses.

合并前的Pieris股东预计将拥有合并公司约18%的股份，合并前的Palvella股东预计将拥有合并公司约82%的股份。预计合并后的公司在拟议合并和同时进行的私人融资结束时将拥有约8050万美元的现金和现金等价物，其中包括在同时进行的私人融资中预期收到的净收益，以及扣除交割前产生的运营费用和估计的交易费用后的净收益。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Get Access to Premium Stock Alerts with RTT Intelligent Investor.

。

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股